tissue polypeptide antigen


Summary: Serological tumor marker composed of a molecular complex of cytokeratins 8, 18, and 19. It is used in the diagnosis and staging of bronchogenic carcinoma.

Top Publications

  1. Buccheri G, Torchio P, Ferrigno D. Clinical equivalence of two cytokeratin markers in mon-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments. Chest. 2003;124:622-32 pubmed
    We have longstanding experience with tissue polypeptide antigen (TPA), a tumor marker of the cytokeratin (CK) family. In the mid-1990s, a new CK marker, CK 19 fragments (CYFRA 21-1), became popular and widely accepted...
  2. Nicolini A, Carpi A, Ferrari P, Anselmi L, Spinelli C, Conte M, et al. The role of tumour markers in improving the accuracy of conventional chest X-ray and liver echography in the post-operative detection of thoracic and liver metastases from breast cancer. Br J Cancer. 2000;83:1412-7 pubmed
    ..3 tumour marker panel has a high value for selecting those patients at high risk of developing clinically evident pulmonary or liver metastases from amongst those subjects with equivocal CXR or equivocal LE. ..
  3. Hedman M, Arnberg H, Wernlund J, Riska H, Brodin O. Tissue polypeptide antigen (TPA), hyaluronan and CA 125 as serum markers in malignant mesothelioma. Anticancer Res. 2003;23:531-6 pubmed
    ..Our results indicate that these three serum markers and mainly TPA might be useful as markers of disease progression and TPA for prediction of survival. ..
  4. Hefler L, Frischmuth K, Heinze G, Sliutz G, Leodolter S, Reinthaller A, et al. Serum concentrations of squamous-cell carcinoma antigen and tissue polypeptide antigen in the follow-up of patients with vulvar cancer. Int J Cancer. 1999;83:167-70 pubmed
    ..evaluate the clinical usefulness of serum concentrations of squamous-cell carcinoma antigen (SCC-Ag) and tissue polypeptide antigen (TPA) in the follow-up of patients with vulvar cancer...
  5. Gion M, Mione R, Gatti C, Dittadi R, Leon A, Nascimben O, et al. Is tissue polypeptide antigen still a useful tumor marker in breast carcinoma? Comparison with CA15.3 and MCA. Tumori. 1990;76:360-4 pubmed
    Serum levels of tissue polypeptide antigen (TPA) are related to the proliferative activity and to the mass of the malignancy, differently from any other available tumor marker. We therefore evaluated TPA in comparison with CA15...
  6. Nicolini A, Ferrari P, Sagripanti A, Carpi A. The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. Br J Cancer. 1999;79:1443-7 pubmed
    ..3 tumour marker panel has a high value in selecting those patients with bone metastases, or at high risk of developing clinically-evident bone metastases, among the large number of subjects with equivocal BS. ..
  7. Naghibalhossaini F, Ay J, Alavi J, Oveisi S, Chahardooli R. Effect of opium smoking on concentrations of carcinoembryonic antigen and tissue polypeptide antigen. Int J Biol Markers. 2004;19:305-9 pubmed
    ..of this work was to evaluate the clinical usefulness of determining carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA) levels in habitual opium smokers...
  8. Ecke T, Schlechte H, Schulze G, Lenk S, Loening S. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation. Anticancer Res. 2005;25:635-41 pubmed
    b>Tissue polypeptide antigen (TPA) is present in the proteolytic fragments of cytokeratins 8, 18 and 19 as a component of the cytoskeleton of nonsquamous epithelia...
  9. Carpelan Holmström M, Haglund C, Lundin J, Alfthan H, Stenman U, Roberts P. Independent prognostic value of preoperative serum markers CA 242, specific tissue polypeptide antigen and human chorionic gonadotrophin beta, but not of carcinoembryonic antigen or tissue polypeptide antigen in colorectal cancer. Br J Cancer. 1996;74:925-9 pubmed
    The prognostic value of preoperative serum concentrations of carcinoembryonic antigen (CEA), CA 242, tissue polypeptide antigen (TPA), specific tissue polypeptide antigen (TPS) and human chorionic gonadotrophin beta (hCG beta) in 251 ..

More Information


  1. Nicolini A, Colombini C, Luciani L, Carpi A, Giuliani L. Evaluation of serum CA15-3 determination with CEA and TPA in the post-operative follow-up of breast cancer patients. Br J Cancer. 1991;64:154-8 pubmed
    ..Contemporaneous measurement of serum CEA levels only slightly increases sensitivity and positive predictive value of TPA-CA15-3 combination. ..
  2. Buccheri G, Ferrigno D. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer. J Thorac Cardiovasc Surg. 2001;122:891-9 pubmed
    ..of predicting the resectability of non-small cell lung cancer by measuring the plasma level of the tissue polypeptide antigen, a marker of the cytokeratin family...
  3. Buccheri G, Ferrigno D. Serum biomarkers of non-neuron-endocrine origin in small-cell lung cancer: a 16-year study on carcinoembryonic antigen, tissue polypeptide antigen and lactate dehydrogenase. Lung Cancer. 2000;30:37-49 pubmed
    ..a total of 619 CEA, 621 tissue polypeptide antigen (TPA), and 616 lactate dehydrogenase (LDH) serum assays were obtained from 160 consecutive SCLC at ..
  4. Tuxen M, Soletormos G, Petersen P, Dombernowsky P. Interpretation of sequential measurements of cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) based on analytical imprecision and biological variation in the monitoring of ovarian cancer. Clin Chem Lab Med. 2001;39:531-8 pubmed
    The main objective with cancer antigen 125 (CA 125), carcinoembryonic antigen (CEA), and tissue polypeptide antigen (TPA) monitoring of ovarian cancer patients is to detect an early change of disease activity with high reliability...
  5. Brokelman W, Holmdahl L, Bergstrom M, Falk P, Klinkenbijl J, Reijnen M. Heating of carbon dioxide during insufflation alters the peritoneal fibrinolytic response to laparoscopic surgery : A clinical trial. Surg Endosc. 2008;22:1232-6 pubmed
    ..Cooling of the peritoneum by unheated carbon dioxide causes increased peritoneal PAI-1 levels, important in peritoneal healing processes. ..
  6. Kwieciński J, Kłak M, Trysberg E, Blennow K, Tarkowski A, Jin T. Relationship between elevated cerebrospinal fluid levels of plasminogen activator inhibitor 1 and neuronal destruction in patients with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2009;60:2094-101 pubmed publisher
    ..Intrathecal release of PAI-1 is increased in patients with NPSLE. This results in impaired fibrinolysis, which might contribute to neuronal and astrocytic damage in NPSLE. ..
  7. Sawant S, Chaukar D, Joshi S, Dange P, Kannan S, Kane S, et al. Prognostic value of tissue polypeptide antigen in oral squamous cell carcinoma. Oral Oncol. 2011;47:114-20 pubmed publisher
    ..Thus, our study indicates that TPA can be a useful tumour marker for the prediction of recurrence and poor prognosis in human oral cancer. ..
  8. Sugiyama Y, Kawaguchi Y. [Tissue polypeptide antigen (TPA)]. Nihon Rinsho. 2005;63 Suppl 8:705-7 pubmed
  9. Bystrom P, Berglund A, Nygren P, Wernroth L, Johansson B, Larsson A, et al. Evaluation of predictive markers for patients with advanced colorectal cancer. Acta Oncol. 2012;51:849-59 pubmed publisher
    ..The ability of the individual tumor markers to predict treatment response and PFS is limited. Changes in marker levels during the first two months of treatment are less informative of outcome. ..
  10. Meduri F, Doni M, Merenda R, Bizzarini M, Neri D, Gerunda G, et al. The role of the leukocyte adherence inhibition (LAI), CA 19-9, and tissue polypeptide antigen (TPA) tests in the diagnosis of pancreatic cancer. Cancer. 1989;64:1103-6 pubmed
    ..These results were significantly better than those by the CA 19-9 and tissue polypeptide antigen (TPA) tests...
  11. Di Lorenzo G, Autorino R, Giordano A, Giuliano M, D Armiento M, Bianco A, et al. FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder. Jpn J Clin Oncol. 2004;34:747-50 pubmed
    ..More studies are required to assess the possible role of this regimen in the treatment of advanced bladder cancer. ..
  12. Eleftheriadou A, Chalastras T, Ferekidou E, Kyriou L, Yiotakis I, Pappas Z, et al. Clinical effectiveness of tumor markers in squamous cell carcinoma of the larynx. Anticancer Res. 2006;26:2493-7 pubmed
    ..CEA indicated a positive correlation only with distant metastasis. Among the four markers, only TPA-M may play a role in monitoring the success of therapy and follow-up in patients with SCC of the larynx. ..
  13. Xu T, Zhang H, Li X, Xie Z, Li X. Enzyme-triggered tyramine-enzyme repeats on prussian blue-gold hybrid nanostructures for highly sensitive electrochemical immunoassay of tissue polypeptide antigen. Biosens Bioelectron. 2015;73:167-173 pubmed publisher
    ..electrochemical immunoassay with sensitivity enhancement was developed for quantitative detection of tissue polypeptide antigen (TPA) by coupling with target-induced tyramine signal amplification on prussian blue-gold hybrid ..
  14. Reinmuth N, Brandt B, Semik M, Kunze W, Achatzy R, Scheld H, et al. Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer. Lung Cancer. 2002;36:265-70 pubmed
    ..When the prognostic impact is confirmed with larger patient numbers this may contribute to the identification of stratification variables for future treatment approaches of NSCLC. ..
  15. Liska V, Holubec L, Treska V, Skalicky T, Sutnar A, Topolcan O, et al. Tumor markers as useful predictors of survival rate after exploratory laparotomy for liver malignancies. Anticancer Res. 2007;27:1887-91 pubmed
    ..It would be very helpful for the planning of palliative oncological therapy for patients with liver malignancies who cannot be treated by surgical therapy. ..
  16. Polberg K, Stepulak A, Stryjecka Zimmer M, Kupisz K, Zawiślak J. [Diagnostic value of tissue polypeptide antigen in serum of larynx cancer patients]. Pol Merkur Lekarski. 2005;19:517-20 pubmed
    b>Tissue polypeptide antigen (TPA) is a serological tumour marker used in the diagnosis, management and follow-up of patients with head and neck cancer...
  17. Boher J, Pujol J, Grenier J, Daures J. Markov model and markers of small cell lung cancer: assessing the influence of reversible serum NSE, CYFRA 21-1 and TPS levels on prognosis. Br J Cancer. 1999;79:1419-27 pubmed
  18. Rebhandl W, Rami B, Turnbull J, Felberbauer F, Paya K, Bancher Todesca D, et al. Diagnostic value of tissue polypeptide-specific antigen (TPS) in neuroblastoma and Wilms' tumour. Br J Cancer. 1998;78:1503-6 pubmed
    ..Serum TPS measurements in children presenting with abdominal masses can help in diagnosing the two commonest extracranial solid malignancies of childhood. Furthermore, TPS could acquire a pivotal role in monitoring therapy. ..
  19. Wang J, Li J, Liu Q. Association between platelet activation and fibrinolysis in acute stroke patients. Neurosci Lett. 2005;384:305-9 pubmed
    ..052, p < 0.0001). Our results indicate increased platelet activation and decreased fibrinolysis in patients with acute atherosclerotic ischemic stroke. Increased platelet activation may be correlated with decreased fibrinolysis. ..
  20. Brokelman W, Holmdahl L, Falk P, Klinkenbijl J, Reijnen M. The peritoneal fibrinolytic response to conventional and laparoscopic colonic surgery. J Laparoendosc Adv Surg Tech A. 2009;19:489-93 pubmed publisher
    ..Peritoneal hypofibrinolysis initiates more rapidly during conventional, compared to laparoscopic, surgery, but at the conclusion of the surgery, the effect was the same. ..
  21. Menéndez López V, Galan J, Fernandez Suarez A, López Celada S, Alcover J, Filella X. Usefulness of tissue polypeptide antigen in the follow-up of bladder cancer. Urology. 2003;62:243-8 pubmed
    To evaluate the sensitivity and specificity of serum tissue polypeptide antigen (TPA) as a tumor marker for monitoring tumor recurrence in a prospective Phase II study...
  22. Leube R, Bosch F, Romano V, Zimbelmann R, Hofler H, Franke W. Cytokeratin expression in simple epithelia. III. Detection of mRNAs encoding human cytokeratins nos. 8 and 18 in normal and tumor cells by hybridization with cDNA sequences in vitro and in situ. Differentiation. 1986;33:69-85 pubmed
    ..Comparison with the reported amino acid sequences of two fragments of human 'tissue polypeptide antigen' (TPA), a widely used serodiagnostic carcinoma marker, revealed sequence identity, indicating that this ..
  23. Soletormos G, Petersen P, Dombernowsky P. Assessment of CA 15.3, CEA and TPA concentrations during monitoring of breast cancer. Clin Chem Lab Med. 2000;38:453-63 pubmed
    The variability of the tumor markers cancer antigen (CA) 15.3, carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA) during steady state concentrations and the rate of increase during progression is described...
  24. Theyer G, Holub S, Durer A, Andert S, Haberl I, Theyer U, et al. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy. Br J Cancer. 1997;75:1515-8 pubmed
  25. Gion M, Tremolada C, Mione R, Della Palma P, Dittadi R, Zari C, et al. Tumor markers in serum of patients with primary squamous cell carcinoma of the esophagus. Tumori. 1989;75:489-93 pubmed
  26. Hu S, Chen G, Wu C, Lan C. Serum tissue polypeptide antigen correlating with clinical course in a patient with mycosis fungoides: a potential disease marker?. Br J Dermatol. 2007;157:423-5 pubmed
  27. Passowicz Muszyńska E, Gisterek I, Marciniak M, Kornafel J, Kołodziej J, Jankowska R. [Tumor markers TPA and Cyfra 21.1 in patients with non-small cell lung cancer after surgery and chemotherapy]. Pol Merkur Lekarski. 2002;13:294-7 pubmed
    ..It seems that establishing of values of Cyfra 21.1 and TPA in the patient's follow up may be useful in recognition of tumour relapse. ..
  28. Bancher Todesca D, Hefler L, Zeisler H, Schatten C, Husslein P, Heinze G, et al. Placental expression of cytokeratin 18 and serum levels of tissue polypeptide antigen in women with pregnancy-induced hypertension. Hypertens Pregnancy. 2001;20:89-98 pubmed
    We hypothesized that placental cytokeratin (CK) 18 expression and serum levels of tissue polypeptide antigen (TPA), a surrogate marker for CK 18, are increased among women with pregnancy-induced hypertension (PIH)...
  29. Finek J, Holubec L, Topolcan O, Pikner R, Sůvová B, Treska V. [Clinical importance of determination of tumor markers during follow-up in breast carcinoma]. Cas Lek Cesk. 2004;143:174-7 pubmed
    ..For the tumor disease follow up only CA 15-3 has sufficient sensitivities (at 95% specificities) for the early diagnosis of the metastatic process. ..
  30. Manci N, Marchetti C, Esposito F, Graziano M, Tomao F, Pastore M, et al. Late breast cancer recurrence to the uterine cervix with a review of the literature. Int J Gynecol Pathol. 2008;27:113-7 pubmed
    ..The adoption of colposcopy in cancer survivors might be an aid to gynecologists in diagnosing cancer recurrence. Cancer survivors might benefit from a more thorough gynecologic examination as compared with the simple Papanicolaou test. ..
  31. Guo H, Wan Y, Tian G, Liu Q, Kang Y, Li Y, et al. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy. Oncol Rep. 2012;27:880-90 pubmed publisher
    ..two groups in terms of improvement of peripheral blood carcinoembryonic antigen and tissue polypeptide antigen after 4 weeks of therapy...
  32. Hu X, Day W, Jones B, Loo W, Chow L. Comparison of TPS with CEA and CA 15.3 in follow-up of Chinese breast cancer patients. Anticancer Res. 2002;22:1865-8 pubmed
    ..However, TPS was associated with neither prognostic factors nor patient survival. In conclusion, TPS is not a good serum tumor marker for breast cancer of Chinese patients, compared with CEA and CA 15.3. ..
  33. Kulpa J, Wojcik E, Radkowski A, Kolodziejski L, Stasik Z. CYFRA 21-1, TPA-M, TPS, SCC-Ag and CEA in patients with squamous cell lung cancer and in chemical industry workers as a reference group. Anticancer Res. 2000;20:5035-40 pubmed
    ..A significant relationship between marker level and survival was observed for CYFRA 21-1 as well as SCC-Ag levels. In a multivariate analysis CYFRA 21-1 and/or TPS remained significant predictors of survival. ..
  34. Aly A, Khandelwal M, Zhao J, Mehmet A, Sammel M, Parry S. Neutrophils are stimulated by syncytiotrophoblast microvillous membranes to generate superoxide radicals in women with preeclampsia. Am J Obstet Gynecol. 2004;190:252-8 pubmed
    ..Serum levels of tissue polypeptide antigen (TPA), which is a marker for STBM, were measured in 25 nulliparous women (10 with mild preeclampsia, 6 ..
  35. Ferrigno D, Buccheri G, Giordano C. Neuron-specific enolase is an effective tumour marker in non-small cell lung cancer (NSCLC). Lung Cancer. 2003;41:311-20 pubmed
    ..of NSE in non-small cell lung cancer (NSCLC), as compared to that of carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA). The study comprised 448 new consecutive NSCLC patients seen from 1996 to 2001...
  36. Womack C, Rasmussen J, Vickers D, Paton C, Osmond P, Davis G. Changes in fibrinolysis following exercise above and below lactate threshold. Thromb Res. 2006;118:263-8 pubmed
    ..05) lower during the >LT test. Our results suggest that exercise <LT can cause fibrinolytic responses and that exercise above LT elicits greater fibrinolytic responses than equicaloric exercise performed below LT. ..
  37. Yao Z, Huang K, Guo J, Li Y, Yu J, Wu F. Screening and determinations of tissue polypeptide antigen by label-free optical immunosensing method. J Nanosci Nanotechnol. 2012;12:112-8 pubmed
    ..novel label-free optical immunosensor with amplified sensitivity has been developed for the detection of tissue polypeptide antigen (TPA)...
  38. Kawamoto H, Fukuda M. [Present conditions and the prospects for biomarker measurement in breast cancer]. Nihon Rinsho. 2007;65 Suppl 6:281-4 pubmed
  39. Gómez de Terreros Caro F, Alvarez Sala R, Prados M, Callol L, Gómez de Terreros Sánchez F, Villamor J. How to express tumor markers in bronchoalveolar lavage. Int J Biol Markers. 2004;19:67-71 pubmed
    ..Tumor marker values can be determined in the BAL fluid, but controversy still exists about how to express the results...
  40. Hefler L, Tempfer C, Frischmuth K, Maenner G, Concin N, Sliutz G, et al. Serum concentrations of tissue polypeptide antigen in patients with vulvar intraepithelial neoplasia and vulvar cancer. Tumour Biol. 2000;21:98-104 pubmed
    The aim of the present study was to evaluate the clinical usefulness of the cytokeratin tumor marker tissue polypeptide antigen (TPA) in patients with vulvar cancer...
  41. Charles M, Morange P, Eschwege E, Andre P, Vague P, Juhan Vague I. Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. Diabetes Care. 1998;21:1967-72 pubmed
    ..Metformin had a significant effect on two factors, tPA antigen and vWF, mainly secreted by the endothelial cells, which suggests an effect of the drug on the production or the metabolism of these two hemostatic proteins. ..
  42. Liska V, Holubec L, Treska V, Vrzalova J, Skalicky T, Sutnar A, et al. Evaluation of tumour markers as differential diagnostic tool in patients with suspicion of liver metastases from breast cancer. Anticancer Res. 2011;31:1447-51 pubmed
    ..markers carcinoembryonic antigen (CEA), carbohydrate antigen CA19-9 (CA19-9), thymidine kinase (TK), tissue polypeptide antigen (TPA), tissue polypeptide-specific antigen (TPS) and cytokeratin 19 fragment (CYFRA 21-1) in ..
  43. Kuno T, Kaizu K. [Use of tumor markers in patients on chronic hemodialysis]. Nihon Rinsho. 2004;62 Suppl 6:391-4 pubmed
  44. Amiri H, Hacke W, Bösel J. [Thrombolytic treatment of acute stroke]. Internist (Berl). 2011;52:1310, 1312-6 pubmed publisher
    ..Acute basilar artery occlusion should be treated in specialized centres using intra-arterial application of urokinase, rt-PA or mechanical recanalization but intravenous thrombolysis beyond the 3 h window is an acceptable alternative. ..
  45. Kokocinska D, Wieczorek P, Partyka R, Jarzab J, Jałowiecki P, Sikora J. The diagnostic utility of S-100B protein and TPA in patients with ischemic stroke. Neuro Endocrinol Lett. 2007;28:693-8 pubmed
    The aim of the study is to asses blood plasma concentrations of S-100B protein and Tissue Polypeptide Antigen (TPA) in patients with confirmed ischemic stroke and to correlate these concentrations with stroke severity...
  46. Mezger J, Permanetter W, Gerbes A, Wilmanns W, Lamerz R. Tumour associated antigens in diagnosis of serous effusions. J Clin Pathol. 1988;41:633-43 pubmed
    ..b>Tissue polypeptide antigen (TPA), alpha fetoprotein, and CA 125 were found to be of little value...
  47. Ecke T, Lenk S, Schlechte H, Loening S. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer. Anticancer Res. 2003;23:957-62 pubmed
    b>Tissue polypeptide antigen (TPA) is a circulating complex of polypeptide fragments from cytokeratins 8, 18 and 19. It is a tumour-related protein. TPA is an indicator of higher cell proliferation...
  48. Sedlaczek P, Frydecka I, Gabrys M, Van Dalen A, Einarsson R, Harłozińska A. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma. Cancer. 2002;95:1886-93 pubmed
  49. Benyamin A, Bayu D, Minhajat R. Association Between PAI-1 Activity Levels and t-PA Antigen with Glycemic Status in Prediabetic Population. Acta Med Indones. 2016;48:200-206 pubmed
    ..04). the level of t-PA antigen and PAI-1 activity were significantly higher in prediabetic subjects than those with NGT; and there was a significant association between glycemic status in prediabetic subjects and PAI-1 activity. ..
  50. Higashi N, Kunimoto H, Kaneko S, Sasaki T, Ishii M, Kojima H, et al. Cytoplasmic c-Fos induced by the YXXQ-derived STAT3 signal requires the co-operative MEK/ERK signal for its nuclear translocation. Genes Cells. 2004;9:233-42 pubmed
    ..Thus, the YXXQ-signal induces c-Fos expression through STAT3 and anchors the new c-Fos in the cytoplasm. In addition, the YXXQ-signal and an Erk signal co-operatively cause c-Fos activation in the nucleus. ..
  51. Hubina E, Kovacs L, Szabolcs I, Rimanóczy E, Czirjak S, Goth M. [Serum tumor marker levels during a 12-months growth hormone replacement therapy in patients with adult growth hormone deficiency]. Orv Hetil. 2002;143:601-5 pubmed
    ..antigen, human choriogonadotropin hormone, alpha-fetoprotein, prostate specific antigen, tissue polypeptide antigen-M, ferritin, gastrointestinal carcinoma antigen, ovarian antigen, breast specific antigen, carcinoma ..
  52. Buccheri G, Ferrigno D. Lung tumour markers in oncology practice: a study of TPA and CA125. Br J Cancer. 2002;87:1112-8 pubmed
    ..This is the first clinical study specifically designed to compare tissue polypeptide antigen and CA 125 tumour associated antigen...
  53. Ruibal A, Arias J, Resino C, Lapeña G, Schneider J, Tejerina A. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation]. Rev Esp Med Nucl. 2001;20:365-8 pubmed
    The tissue-specific polypeptide antigen (TPS) is an epitope of the tissue polypeptide antigen (TPA) which is defined by the M3 monoclonal antibody and is related to cytokeratin 18...
  54. Ikarashi T, Takeuchi S. Immunohistochemical localization of placental proteins and tumor-associated antigens in endometrial cancer and endometrial hyperplasia. Nihon Sanka Fujinka Gakkai Zasshi. 1987;39:1634-40 pubmed
    ..protein A (PAPP-A), pregnancy-specific beta 1-glycoprotein (SP1), alpha 1-anti-trypsin (alpha-AT), and tissue polypeptide antigen (TPA)...
  55. Lindmark G, Bergstrom R, Pahlman L, Glimelius B. The association of preoperative serum tumour markers with Dukes' stage and survival in colorectal cancer. Br J Cancer. 1995;71:1090-4 pubmed
    The tumour markers carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), TPS, CA 19-9, CA 50 and CA 242 were analysed in serum from 203 potentially curable colorectal cancer patients...
  56. Treska V, Topolcan O, Vrzalova J, Slauf F, Liska V, Skalicky T, et al. [Can tumor markers predict outcomes of portal vein branch embolization in patients with primary inoperable liver tumors?]. Rozhl Chir. 2011;90:285-9 pubmed
    ..Tumor markers may be significant in predicting PVE outcomes in patients with primary inoperable liver tumors. However, in order to make final conclusions on their clinical significance, larger patient group studies should be performed. ..
  57. Pardos M, Alvarez Sala R, Terreros Caro F, Gomez L, Gomez de Terreros F, Villamor J. The concentrations of five tumor markers in both BAL fractions in lung cancer patients in relation to cigarette smoking. Tumori. 1999;85:454-7 pubmed
    ..Some of these markers, such as carcinoembryonic antigen, neuron-specific enolase, tissue polypeptide antigen (TPA), tissue polypeptide-specific antigen (TPS) and CYFRA 21...
  58. Bedkowska G, Ławicki S, Szmitkowski M. [Molecular markers of carcinogenesis in the diagnostics of cervical cancer]. Postepy Hig Med Dosw (Online). 2009;63:99-105 pubmed
    ..be useful in the diagnostics of cervical cancer, for example squamous cell carcinoma antigen (SCC-Ag), tissue polypeptide antigen (TPA), and CYFRA 21-1, as well as some cytokines such as vascular endothelial growth factor (VEGF), ..
  59. Mady E. Cytokeratins as serum markers in egyptian bladder cancer. A comparison of CYFRA 21-1, TPA and TPS. Int J Biol Markers. 2001;16:130-5 pubmed
    ..Combined use of two of the three markers did not raise the sensitivities obtained by single determination of CYFRA 21-1. The present study suggests that serum CYFRA 21-1 could be a marker of choice in bladder cancer. ..
  60. Zheng H, He B, Luo R, You C, Mai G, Lu H. [Clinical study of serum tissue polypeptide-specific antigen in breast cancer]. Di Yi Jun Yi Da Xue Xue Bao. 2003;23:823-5 pubmed
    ..05). Serum TPS can be used as a very useful and sensitive tumor marker in the diagnosis of breast cancer, especially in case of bone metastasis, and may be of great value in clinical decision-making and assessment of therapeutic effect. ..
  61. van der Gaast A, van Putten W, Oosterom R, Cozijnsen M, Hoekstra R, Splinter T. Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer. Br J Cancer. 1991;64:369-72 pubmed
    ..Thymidine kinase (TK), tissue polypeptide antigen (TPA) and lactate dehydrogenase (LDH) but not neuron specific enolase (NSE) correlated significantly ..
  62. Nicolini A, Carpi A, Ferrari P, Pieri L. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations. Tumour Biol. 2003;24:275-80 pubmed
    To assess the value of the serum carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and breast cancer-associated antigen CA15.3 (CEA-TPA-CA15...
  63. Riedel U, Schonfeld N, Savaser A, Serk M, Loddenkemper R. [Diagnostic value of the tumor markers TPA-M, CYPFRA 21-1 and CEA in pleural effusion. Prospective comparison of thoracoscopic investigations in patients with pleural effusion]. Pneumologie. 1999;53:471-6 pubmed
    ..CYFRA 21-1 (Cytokeratin 19-Fragment) and TPA-M, a new monoclonal-based radioimmunoassay for TPA (Tissue Polypeptide Antigen), were measured in pleural fluid and sera of 125 consecutive patients who underwent medical thoracoscopy...
  64. Pan Q, Zhang X, Xu Z, Zheng S. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer]. Ai Zheng. 2002;21:196-9 pubmed
    ..CK19mRNA with other tumor markers, such as carcinoembryanic antigen(CEA), neuron-specific Enolase(NSE), tissue polypeptide antigen(TPA), would improve the diagnosis of lung cancer...
  65. Barak V, Goike H, Panaretakis K, Einarsson R. Clinical utility of cytokeratins as tumor markers. Clin Biochem. 2004;37:529-40 pubmed
    ..The three most applied cytokeratin markers used in the clinic are tissue polypeptide antigen (TPA), tissue polypeptide specific antigen (TPS), and CYFRA 21-1...
  66. Ishihara A, Mori T, Koono M. Diffuse pagetoid squamous cell carcinoma of the esophagus combined with choriocarcinoma and mucoepidermoid carcinoma: an autopsy case report. Pathol Int. 2002;52:147-52 pubmed
    ..The invasive squamous cell carcinoma, mucoepidermoid carcinoma and choriocarcinoma are suggested to have originated from the overlying SCCIS. ..
  67. Fukasawa I, Kousaka N, Kun Z, Inaba N. [Tumor markers in uterine cancers]. Gan To Kagaku Ryoho. 2002;29:333-40 pubmed
    ..Combination assay of several tumor markers including cancer antigen 125 (CA125) as a core marker may be of greater diagnostic value in cases of uterine corpus carcinoma. ..
  68. Brunetti G, Bossi A, Baiardi P, Jedrychowska I, Pozzi U, Bacchella L, et al. Soluble interleukin 2 receptor (sIL2R) in monitoring advanced lung cancer during chemotherapy. Lung Cancer. 1999;23:1-9 pubmed
    ..In this case any variations in sIL2R serum levels are likely to relate to the spread of the neoplasia rather than to the host immune response. ..
  69. Buccheri G, Ferrigno D. Lung tumor markers of cytokeratin origin: an overview. Lung Cancer. 2001;34 Suppl 2:S65-9 pubmed
    ..Among them, Tissue Polypeptide Antigen (TPA), Tissue Polypeptide-Specific Antigen (TPS) and Cytokeratin-19-Fragments (Cyfra 21-1) are the most ..
  70. Nicolini A, Carpi A, Ferrari P, Rossi G. Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients: a retrospective longitudinal study. Cancer Lett. 2008;263:122-9 pubmed publisher
    ..The CEA-TPA-CA15.3 tumour marker panel accurately predicted metastatic disease progression and immunotherapy significantly prolonged the CEA-TPA-CA15.3 lead time. This can be used for anticipating salvage treatment in these patients. ..
  71. Prados C, Alvarez Sala R, Gómez de Terrero J, Callol L, Garcia Rio F, Gómez Carrera L, et al. An evaluation of tissue polypeptide antigen (TPA) in the two bronchoalveolar lavage fractions of lung cancer patients. Jpn J Clin Oncol. 2000;30:215-20 pubmed
    ..markers for the follow-up, treatment monitoring and prognosis evaluation of lung cancer and among these, tissue polypeptide antigen (TPA) plays an important role...
  72. Orbach H, Zandman Goddard G, Amital H, Barak V, Szekanecz Z, Szucs G, et al. Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci. 2007;1109:385-400 pubmed
    ..Prolactin (PRL), ferritin, vitamin D, and the tumor marker tissue polypeptide antigen (TPA) were measured in autoimmune diseases: systemic lupus erythematosus (SLE), systemic sclerosis (SSc),..
  73. Szymanski L, Kessler C, Fernhall B. Relationship of physical fitness, hormone replacement therapy, and hemostatic risk factors in postmenopausal women. J Appl Physiol (1985). 2005;98:1341-8 pubmed
    ..Thus fitness is more strongly related to these hemostatic risk factors compared with HRT since HRT did not affect these hemostatic variables in fit postmenopausal women. ..
  74. Yu L, Sangster N, Perez A, McCormick P. The bHLH protein MyoR inhibits the differentiation of early embryonic endoderm. Differentiation. 2004;72:341-7 pubmed
    ..5 and 5.5 dpc contributes to the embryonic death of mouse embryos overexpressing exogenous MyoR and consequently that MyoR may serve as a repressor of embryonal endoderm differentiation. ..
  75. Barber H. New frontiers in ovarian cancer diagnosis and management. Yale J Biol Med. 1991;64:127-41 pubmed
    ..The expanding areas of research in cancer are starting to dispel the doom and gloom of the last three decades with a spirit of optimism for the diagnosis and treatment of ovarian cancer, as the new century approaches. ..
  76. Fuchs T, Michniewicz J, Zimmer M. [Use of color Doppler technique and estimation of CA 125 amd TPA levels in blood serum for the diagnosis of adnexal masses]. Ginekol Pol. 2002;73:1038-43 pubmed
    ..Color doppler technique is a useful tool in diagnosis of adnexal masses and has higher sensitivity and specificity compared with measurements of Ca125, TPA levels and single tumor features achieved during transvaginal ultrasound. ..
  77. Kasimir Bauer S, Schleucher N, Weber R, Neumann R, Seeber S. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival. Oncol Rep. 2003;10:475-82 pubmed
    ..The tumour marker tissue polypeptide antigen (TPA) and Cyfra 21-1 were the only marker which significantly correlated with OS...
  78. Nicolini A, Ferrari P, Duffy M, Antonelli A, Rossi G, Metelli M, et al. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival. Arch Surg. 2010;145:1177-83 pubmed publisher
    ..9, and CA72.4 TM panel and abdominal ultrasonography allows early detection of most recurrences. Patients can then undergo radical metastasectomy, with potentially improved overall survival. ..
  79. Bhatavdekar J, Patel D, Vora H, Balar D. Circulating markers and growth factors as prognosticators in men with advanced tongue cancer. Tumour Biol. 1993;14:55-8 pubmed
    ..0 and > 15.0 ng/ml; p < 0.001). Hence, prolactin may provide an independent predictor of short-term prognosis in patients with advanced tongue cancer. ..
  80. Plebani M, Basso D, Navaglia F, De Paoli M, Tommasini A, Cipriani A. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results?. Br J Cancer. 1995;72:170-3 pubmed
  81. Seo J. [An immunohistochemical study on primary carcinoma of the liver]. J UOEH. 1989;11:429-39 pubmed
    ..by means of the ABC method for carcinoembryonic antigen (CEA), epithelial membrane antigen (EMA), tissue polypeptide antigen (TPA) and keratin...
  82. Bedkowska G, Lawicki S, Szmitkowski M. [New tumour markers useful in diagnostics and monitoring of cervical cancer]. Przegl Lek. 2007;64:1022-7 pubmed
  83. Frena A. SPan-1 and exocrine pancreatic carcinoma. The clinical role of a new tumor marker. Int J Biol Markers. 2001;16:189-97 pubmed
    ..This article discusses the clinical evaluation of SPan-1 and its comparison with established markers such as CA 19.9, CEA, TPA and CA 242...
  84. Puoti C, Bellis L, Guarisco R, Costanza O, Felici R, Spilabotti L, et al. Quantitation of tissue polypeptide antigen (TPA) in hepatic and systemic circulation in patients with chronic liver diseases. J Gastroenterol Hepatol. 2009;24:1847-51 pubmed publisher
    Abnormal serum tissue polypeptide antigen (TPA) values are commonly found in patients with chronic liver damage and liver cirrhosis even in the absence of malignancies...